论文部分内容阅读
目的 探讨雷替曲塞联合多西他塞对进展期胃癌患者血浆血管内皮细胞生长因子(VEGF)的影响.方法 选取就诊的进展期胃癌患者28 例,对患者进行雷替曲塞联合多西他塞药物化疗4～6 个周期,测定化疗前后血浆VEGF水平.结果 化疗前1 d、化疗后1 d、1 周、1 个月、4～6 个化疗周期后的VEGF水平分别为(298.5±23.4)、(473.5±68.5)、(268.3±47.9)、(290.7±32.4)、(232.4±21.6)ng/L;化疗后1 d、1 周、4～6 个化疗周期后的VEGF水平与化疗前比较差异有统计学意义(P＜0.05);化疗4～6 个周期后,总有效率达到46.4%,达到ORR患者的VEGF水平为(202.4±23.4)ng/L.结论联合药物化疗后进展期胃癌患者VEGF水平有明显降低.“,”Objective To investigate the effect of raltitrexed combined with docetaxel on plasma vascular endothelial growth factor (VEGF) in patients with advanced gastric cancer. Methods Twenty-eight patients with advanced gastric cancer were enrolled in this study. The patients were treated with raltitrexed combined with docetaxel for 4-6 cycles and the plasma levels of VEGF were measured before and after chemotherapy. Results The VEGF levels at 1 d before chemotherapy, 1 d, 1 week and 1 month after chemotherapy and after 4-6 cycles of chemotherapy were (298.5±23.4), (473.5±68.5), (268.3±47.9), (290.7±32.4), and (232.4±21.6) ng/L, respectively. The levels of VEGF at 1 d and 1 week after chemotherapy and after 4-6 cycles of chemotherapy were significantly different from those before chemotherapy (P＜0.05). After 4-6 cycles of chemotherapy, the total effective rate was 46.4%, and the VEGF level of ORR patients was (202.4±23.4) ng/L. Conclusion The level of VEGF was significantly decreased after the combination of raltitrexed and docetaxel.